Advertisement
ELV vs HUM
Which Stock Would AI Choose? Elevance Health (ELV) vs. Humana (HUM) Stock Comparison
Key Takeaways
- Elevance Health (ELV) and Humana (HUM) are leading managed care organizations with significant exposure to Medicare Advantage and commercial health insurance markets.
- Recent market activity shows HUM delivering substantially stronger year-to-date returns compared to ELV, reflecting differences in momentum and investor sentiment.
- Both companies face near-term earnings scrutiny, with ELV reporting second-quarter 2026 results on July 15 and HUM on July 29.
- ELV has seen multiple analyst price target increases in early July 2026, while HUM has recorded notable one-year gains exceeding 68%.
- Sector-wide pressures including medical cost trends and regulatory factors influence relative performance and risk profiles for both stocks.
- Market positioning favors scale and diversification, with ELV maintaining a larger market capitalization than HUM.
Introduction
This comparison examines Elevance Health (ELV) and Humana (HUM), two prominent players in the U.S. managed care sector. Both companies operate large health insurance businesses with meaningful Medicare Advantage exposure, making them relevant for investors tracking healthcare utilization trends, reimbursement dynamics, and cost management. Traders and portfolio managers focused on sector rotation, relative valuation, or defensive growth characteristics may find the analysis useful for assessing positioning within the broader healthcare services landscape. The review draws on recent market data and observable performance metrics to highlight contrasts without forward-looking speculation.
Elevance Health (ELV) Overview and Recent Performance
Elevance Health (ELV) provides health benefits and related services across commercial, Medicare, and Medicaid segments. In recent weeks, the stock has traded near its 52-week high amid analyst upgrades, including price target increases from multiple firms in early July 2026. Year-to-date returns stand at approximately 21%, supported by prior guidance raises and share repurchase activity. Upcoming second-quarter 2026 earnings, scheduled for July 15, represent a key near-term catalyst, with analysts anticipating year-over-year earnings pressure tied to medical costs. Sentiment has remained constructive on operational scale and capital return programs, though broader sector cost concerns have tempered broader gains relative to peers.
Humana (HUM) Overview and Recent Performance
Humana (HUM) focuses primarily on Medicare Advantage and specialty health products. The stock has posted robust recent market activity, with year-to-date returns near 56% and one-year gains exceeding 68%. Trading near 52-week highs in early July 2026, performance has been influenced by favorable reimbursement outlooks and volume trends in government-sponsored programs. Second-quarter 2026 results are slated for release on July 29. Investor interest has centered on margin stability and membership growth, though earnings visibility remains a focal point ahead of the report. Overall positioning reflects stronger relative momentum within the managed care group during the recent period.
Trending AI Robots
Tickeron maintains a curated Trending AI Robots section that highlights select AI trading bots from a broader library of hundreds of bots trading thousands of tickers. Only those demonstrating the strongest alignment with prevailing market conditions receive placement in this featured area. Available bots encompass a wide range of trading styles, strategies, timeframes, performance statistics, and ticker universes. Historical data on these systems often show varied win rates, drawdowns, and return profiles depending on market regimes. Readers interested in exploring automated trading approaches can review the full selection on the Trending AI Robots page for additional details.
Head-to-Head Comparison
Elevance Health (ELV) operates a more diversified platform with larger overall scale and a broader mix of commercial and government lines, while Humana (HUM) maintains heavier concentration in Medicare Advantage. Recent momentum favors HUM, evidenced by substantially higher year-to-date and trailing twelve-month returns. Both stocks exhibit relatively low volatility compared with the broader market, yet ELV has attracted more frequent analyst target revisions in the latest period. Risk factors for each include medical loss ratio trends and regulatory changes affecting reimbursement rates. Sector exposure remains comparable, though differences in membership mix and cost management execution create distinct trade-offs for relative positioning within healthcare portfolios.
Tickeron AI Verdict
Based on observable trend consistency and relative momentum in recent market activity, Tickeron’s AI would currently assign a higher probabilistic preference to Humana (HUM) over Elevance Health (ELV). Stronger year-to-date performance and positioning near recent highs suggest more sustained upward trajectory amid shared sector dynamics. This assessment reflects measurable price behavior and catalyst timing rather than definitive outcomes.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ELV is a Hold and HUM is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ELV’s FA Score shows that 3 FA rating(s) are green whileHUM’s FA Score has 3 green FA rating(s).
- ELV’s FA Score: 3 green, 2 red.
- HUM’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ELV’s TA Score shows that 4 TA indicator(s) are bullish while HUM’s TA Score has 3 bullish TA indicator(s).
- ELV’s TA Score: 4 bullish, 4 bearish.
- HUM’s TA Score: 3 bullish, 5 bearish.
Price Growth
ELV (@Managed Health Care) experienced а +4.16% price change this week, while HUM (@Managed Health Care) price change was +3.34% for the same time period.
The average weekly price growth across all stocks in the @Managed Health Care industry was +0.83%. For the same industry, the average monthly price growth was +7.45%, and the average quarterly price growth was +35.30%.
Reported Earning Dates
ELV is expected to report earnings on Jul 15, 2026.
HUM is expected to report earnings on Jul 29, 2026.
Industries' Descriptions
@Managed Health Care (+0.83% weekly)Managed healthcare industry focuses on providing health/medical and disability insurance plans, generally intended to reduce the cost of for-profit health care. The insurance products might be provided through employer-paid (fully or partly) insurance and benefit programs, or through Medicare/Medicaid. Some of the largest providers of managed health care include Aetna, Humana Inc., and Cigna, and UnitedHealthcare.
| ELV | HUM | ELV / HUM | |
| Capitalization | 92.3B | 48.7B | 190% |
| EBITDA | N/A | N/A | - |
| Gain YTD | 22.531 | 59.694 | 38% |
| P/E Ratio | 18.02 | 43.33 | 42% |
| Revenue | 200B | 137B | 146% |
| Total Cash | N/A | N/A | - |
| Total Debt | 31.8B | 14B | 227% |
ELV | HUM | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 7 Undervalued | 11 Undervalued | |
PROFIT vs RISK RATING 1..100 | 84 | 100 | |
SMR RATING 1..100 | 98 | 95 | |
PRICE GROWTH RATING 1..100 | 18 | 3 | |
P/E GROWTH RATING 1..100 | 26 | 6 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ELV's Valuation (7) in the Managed Health Care industry is in the same range as HUM (11). This means that ELV’s stock grew similarly to HUM’s over the last 12 months.
ELV's Profit vs Risk Rating (84) in the Managed Health Care industry is in the same range as HUM (100). This means that ELV’s stock grew similarly to HUM’s over the last 12 months.
HUM's SMR Rating (95) in the Managed Health Care industry is in the same range as ELV (98). This means that HUM’s stock grew similarly to ELV’s over the last 12 months.
HUM's Price Growth Rating (3) in the Managed Health Care industry is in the same range as ELV (18). This means that HUM’s stock grew similarly to ELV’s over the last 12 months.
HUM's P/E Growth Rating (6) in the Managed Health Care industry is in the same range as ELV (26). This means that HUM’s stock grew similarly to ELV’s over the last 12 months.
| ELV | HUM | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 67% | 4 days ago 66% |
| Stochastic ODDS (%) | 4 days ago 53% | 4 days ago 65% |
| Momentum ODDS (%) | 4 days ago 65% | 4 days ago 69% |
| MACD ODDS (%) | 4 days ago 65% | 4 days ago 58% |
| TrendWeek ODDS (%) | 4 days ago 58% | 4 days ago 66% |
| TrendMonth ODDS (%) | 4 days ago 56% | 4 days ago 61% |
| Advances ODDS (%) | 12 days ago 56% | 5 days ago 60% |
| Declines ODDS (%) | 14 days ago 56% | 8 days ago 67% |
| BollingerBands ODDS (%) | 4 days ago 64% | 4 days ago 75% |
| Aroon ODDS (%) | 4 days ago 56% | 4 days ago 59% |
Advertisement
ELV and
Correlation & Price change
A.I.dvisor indicates that over the last year, ELV has been loosely correlated with UNH. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if ELV jumps, then UNH could also see price increases.
HUM and
Correlation & Price change
A.I.dvisor indicates that over the last year, HUM has been loosely correlated with UNH. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if HUM jumps, then UNH could also see price increases.